Category - Developments

Developments

Larimar reports positive data from study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ: LRMR) has announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered...

September 30, 2025

Developments

Anebulo announces first dose in SAD study of IV selonabant for ACI

Anebulo Pharmaceuticals (NASDAQ: ANEB) has announced first patients dosed in its Phase 1 single ascending dose (SAD) study intravenous selonabant—under development for acute cannabis-induced (ACI) toxicity—in healthy...

September 26, 2025

Developments

ME secures U.S. patent for lead G-CSF antibody candidate

Me Therapeutics Holdings (CSE: METX; FSE: Q9T) has announced that the United States Patent Office (USPTO) has granted its subsidiary, ME Therapeutics, a patent for its lead G-CSF antibody candidate. According to ME, the...

September 26, 2025

Developments

USPTO grants Nexalin patent for next-gen HALO Clarity device

Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity...

September 25, 2025

Developments

CIPO grants NOA to Moleculin for patent covering Annamycin

Moleculin Biotech (NASDAQ: MBRX) announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance (NOA) for a patent covering methods of making a preliposomal Annamycin lyophilizate with...

September 25, 2025

Developments

TGA approves MediWound’s NexoBrid for burn management in Australia

MediWound (NASDAQ: MDWD) has announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid—an enzymatic therapy for the removal of eschar in both adult and pediatric...

September 25, 2025

Developments

GeoVax expands with additional solid tumor targets for Gedeptin

GeoVax Labs (NASDAQ: GOVX) has announced the expansion of its oncology development strategy to evaluate additional solid tumor targets for Gedeptin—its gene-directed enzyme prodrug therapy. According to GeoVax, the...

September 24, 2025

Developments

IGC announces pre-clinical data for TGR-63 in AD

IGC Pharma (NYSE: IGC) has announced preclinical findings on its investigational small molecule candidate for Alzheimer’s disease (AD) demonstrating that TGR-63 extends its therapeutic potential beyond previously...

September 24, 2025

Developments

Hemogenyx, Cellin sign LOI to commercialize cell therapy for R/R AML in Estonia

Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the signing of a letter of intent (LOI) with closely held Cellin Technologies to explore the commercialization of its HG-CT-1 CAR-T cell therapy for the treatment of...

September 23, 2025

Developments

EC and Swissmedic approve KalVista’s oral treatment for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) announced that the European Commission (EC) and Swiss Agency for Therapeutic Products (Swissmedic) have approved EKTERLY (sebetralstat), a novel, oral plasma kallikrein inhibitor...

September 19, 2025

Category - Developments

Subscribe